1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E9DAFE45F4455BA1002587840058365D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-how-pharma-utilizing-IME-grants-for-patient-education-medical-sponsorships?OpenDocument
18
19OpenDocument
2052.90.49.108
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Education

How Pharma is Utilizing IME Grants for Patient Education and Medical Sponsorships

ID: 5706


Features:

15 Info Graphics

20 Data Graphics

120 Metrics

5 Narratives


Pages/Slides: 42


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “How Pharma is Utilizing IME Grants for Patient Education and Medical Sponsorships”

STUDY OVERVIEW

Pharma has traditionally used its Independent Medical Education grant program to fund medical education support and programs for HCP-oriented education. But as patient education programs have expanded, pharma has been using the IME grant system for patient education as well. In addition, some use IME grants to support medical sponsorships at conferences and other locations.

Best Practices, LLC conducted this study to highlight current trends and future directions for how pharma is utilizing IME programs for medical patient education activities, sponsorships, and corporate memberships.


Data segmented by respondent’s geographical responsibility – US vs. Global + US vs. Global ex-US


KEY TOPICS

  • Executive Summary
  • IME Grant Support for Patient Medical Education Activities
  • Medical Sponsorships/Corporate Memberships Management

SAMPLE METRICS
  • Patient education activities through IME grant programs
  • Reasons for benchmark organizations supporting or not supporting patient education activities through their IME grant programs
  • Other departments involved in supporting patient education
  • Association between medical education programs for patients and HCPs
  • Limitations and/or concerns faced by benchmark organizations regarding supporting patient education activities with IME grants
  • Impact of patient advocacy groups on medical education programs
  • Management and oversight of medical sponsorships and corporate memberships
  • Platforms used for medical sponsorship management
  • Types of sponsorships managed by Medical Affairs group
  • Differentiation between Medical Affairs-related sponsorship requests and sponsorship requests for other functions such as commercial
  • Nature of commercial and Medical Affairs sponsorship requests
  • Types of sponsorships managed by Medical Affairs group
  • Types of medical requests received through the same platform as IME grant requests

SAMPLE KEY FINDINGS
  • Expand patient education programs by including IME grants as a funding source: Patient-focused education can produce data that informs medical education strategy for HCP-focused education.
  • IME platform is good tool for independent, patient-oriented activities: Investing in a platform for IME-related activities provides a one-stop information source for medical activities; different pathways allow for easy use across activities. In addition, the platform can be adopted globally so it is easier to track activities, costs across regions.

METHODOLOGY

Best Practices, LLC engaged 32 leaders from 27 pharmaceutical companies through a benchmarking survey
.

Industries Profiled:
Pharmaceutical; Health Care; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Consulting; Biopharmaceutical


Companies Profiled:
AbbVie; Merck; Astellas; Merck Serono; Bayer; Eisai; Teva Pharmaceutical Industries Ltd; Roche; GlaxoSmithKline ; AstraZeneca; Biogen; bioMerieux; Allergan; Sanofi Genzyme; Otsuka Pharmaceutical Development & Commercialization; Inc. (OPDC); Sandoz; Baxter BioScience; Ipsen; Merz Pharma; MEDiSTRAVA; Kyowa Kirin; CSL Behring; Grunethal; GRAIL; Apellis Pharmaceuticals; Rhythm Pharmaceuticals; Taiho Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.